Bruker Corp(BRKR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.7 | Insider Own | 27.15% | Shs Outstand | 152.3M | Perf Week | -9.27% |
| Market Cap | 8.16B | Forward P/E | 22.36 | EPS next Y | 12.78% | Insider Trans | -0.04% | Shs Float | 111.0M | Perf Month | -6.09% |
| Enterprise Value | 9.82B | PEG | 1.49 | EPS next Q | 0.42 | Inst Own | 93.94% | Short Float | 10.62% | Perf Quarter | -2.49% |
| Income | -0.11B | P/S | 2.33 | EPS this Y | 16.06% | Inst Trans | 4.28% | Short Ratio | 5.44 | Perf Half Y | 45.48% |
| Sales | 3.50B | P/B | 3.43 | EPS next 5Y | 15.05% | ROA | -1.15% | Short Interest | 11.79M | Perf YTD | 13.67% |
| Book/sh | 15.63 | P/C | 36.67 | EPS past 3/5Y | - | ROE | -3.4% | 52W High | -17.99% ($65.30) | Perf Year | 75.63% |
| Cash/sh | 1.46 | P/FCF | 86.89 | Sales past 3/5Y | 10.74% 11.57% | ROIC | -1.7% | 52W Low | 77.97% ($30.09) | Perf 3Y | -12.7% |
| Dividend Est. | $0.15 (0.28%) | EV/EBITDA | 18.55 | EPS Y/Y TTM | -233.85% | Gross Margin | 47.29% | Volatility(W/M) | 4.98% 4.32% | Perf 5Y | -40.35% |
| Dividend TTM | 0.2 | EV/Sales | 2.8 | Sales Y/Y TTM | 1.65% | Oper. Margin | 8.54% | ATR (14) | 2.73 | Perf 10Y | 144.52% |
| Dividend Ex-Date | 2026/9/21 | Quick Ratio | 0.92 | EPS Q/Q | -924.35% | Profit Margin | -3.05% | RSI (14) | 40.48 | Recom | 2.13 |
| Dividend Gr. 3/5Y | - 4.56% | Current Ratio | 1.85 | Sales Q/Q | 5.15% | SMA20 | -7.1% ($57.64) | Beta | 1.25 | Target Price | $59.23 |
| Payout | - | Debt/Eq | 0.77 | Earnings | 2026/8/4 | SMA50 | -8.39% ($58.45) | Rel Volume | 0.87 | Prev Close | $54.43 |
| Employees | 11085 | LT Debt/Eq | 0.76 | EPS/Sales Surpr. | 27.34% -1.77% | SMA200 | 11.08% ($48.21) | Avg Volume(3M) | 2.17M | Price | $53.55 |
| IPO | 2000/8/4 | Option/Short | Yes/Yes | Trades | 18835 | Volume | 1,882,888 | Change | -1.62% |
Company
BRKR is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A U.S. scientific instrumentation company that supplies advanced analytical and research equipment, such as mass spectrometers and nuclear magnetic resonance systems, to pharmaceutical, biotech, and research institutions. Its performance is largely driven by research and development demand, along with recurring revenue from consumables and services.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
Upcoming eventsNext ex-dividend (upcoming)
Ex-dividend September 21
BRKR has weak earning power
8.54% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +16.1% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -12.7% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 0.28% annually in dividends.
Tap to view numbers
Ownership is about average
Institutions hold 93.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
TINY 0.07%
FBT 0.04%
SPFF 0.02%
MGMT 0.02%
TSCV 0.02%It ranks #4 in the industry
Based on market cap of $8B.
BRKR $8B PER -
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is BRKR?
BRKR belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of BRKR?
The market cap of BRKR is approximately $8.2B, ranking 1,063 within its sector.
Does BRKR pay dividends?
BRKR has a dividend yield of approximately 0.28%, with an annual dividend of $0.15.
What is the 52-week high and low for BRKR?
BRKR has recorded a 52-week high of $65.30 and a low of $30.09.
